Razelle Kurzrock, MD

Articles by Razelle Kurzrock, MD

Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing

BySabrina Serani,Aditya Shreenivas, MD, MS,Razelle Kurzrock, MD

September 15th 2026

Drs Aditya Shreenivas and Razelle Kurzrock break down a 200,000-tumor real-world study on HER2 IHC, ERBB2 alterations, and pan-cancer testing implications.

Latest Updated Articles

Razelle Kurzrock, MD

Articles by Razelle Kurzrock, MD

Rethinking HER2: A Pan-Cancer Look at IHC, ERBB2, and Tumor-Agnostic Testing

Latest Updated Articles

Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways

FDA Approves Reduced Monitoring Time for First 2 Tarlatamab Doses

Landmark ctDNA Testing Offers an Early Window Into Immunotherapy Response in NSCLC

Frontline Activity Seen With Zidesamtinib in ROS1+ NSCLC

FDA Approves Aminolevulinic Acid Gel With PDT for Superficial Basal Cell Carcinoma

FDA Approves Pixclara, First FET-PET Agent for Glioma Imaging